WO2002043484A2 - Embalming fluid - Google Patents

Embalming fluid Download PDF

Info

Publication number
WO2002043484A2
WO2002043484A2 PCT/GB2001/005337 GB0105337W WO0243484A2 WO 2002043484 A2 WO2002043484 A2 WO 2002043484A2 GB 0105337 W GB0105337 W GB 0105337W WO 0243484 A2 WO0243484 A2 WO 0243484A2
Authority
WO
WIPO (PCT)
Prior art keywords
weight
embalming
fluid
disinfectant
polymer
Prior art date
Application number
PCT/GB2001/005337
Other languages
French (fr)
Other versions
WO2002043484A3 (en
Inventor
Dermot Christopher John Barrow
Original Assignee
Aardbalm Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aardbalm Limited filed Critical Aardbalm Limited
Priority to AU5276802A priority Critical patent/AU5276802A/en
Priority to AU2002252768A priority patent/AU2002252768B2/en
Priority to EP01998221A priority patent/EP1365646B1/en
Priority to CA2430502A priority patent/CA2430502C/en
Priority to DE60129851T priority patent/DE60129851T2/en
Publication of WO2002043484A2 publication Critical patent/WO2002043484A2/en
Publication of WO2002043484A3 publication Critical patent/WO2002043484A3/en
Priority to US10/449,502 priority patent/US8015677B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00Preservation of bodies of humans or animals, or parts thereof

Definitions

  • This invention relates to an embalming fluid for use in an embalming process.
  • Embalming was developed and widely practised in ancient Egypt where, from around 6000 BC to 600 AD, 400 million bodies were mummified. The processes involved in traditional Egyptian embalming have led to the remarkable preservation of many bodies.
  • the embalming process nowadays differs markedly from the religious practices of ancient Egypt; the purpose is partly cosmetic (to improve the appearance of the body, and thereby reduce the distress caused to relatives of the deceased) and partly preservative, although the main aim is to ensure that the body remains in a hygienic condition during the period up to burial or cremation, rather than providing long-lasting preservation of the tissues.
  • the modern embalming process involves flushing out the blood from the circulatory system of the body and replacing it with an embalming fluid which has a stabilising and protecting action on the body.
  • the embalming fluid is injected into the arterial system of the cadaver and directly into some organs. Displaced body fluids are treated and disposed of via the public sewerage system or more usually by a contracted disposal firm.
  • the eyes are closed. This is usually accomplished with a small curved plastic disc called an "eye cap” placed under the eyelid. Perforations in the cap are sometimes present to help hold the eye lid in place.
  • the mouth is closed. This is usually accomplished by the placing of a specially designed "tack" in the upper and lower jaw. Each tack has a fine wire attached. By twisting the two wires together, the jaw is thus closed and the lips are set to the natural lip line using a cream to retain the proper position and to prevent dehydration.
  • the lower body orifice (s) may be plugged to prevent leakage .
  • the embalming solution is prepared.
  • the modern embalming machine consists of a 2-3 gallon reservoir and an electric pump.
  • a tube which is attached to the machine is inserted into the artery.
  • a slightly larger tube is placed into the accompanying vein. This tube is attached via a hose to a collecting tank.
  • the fluid is injected into the artery under pressure by the embalming machine. As the blood is displaced by the fluid going in, it is forced out of the body from the vein and is disposed of. The pressure forces the embalming fluid into the capillaries and eventually to the cells of the body. After sufficient solution (typically approximately 2-10 litres depending on body size, more particularly vascular capacity) of solution are injected into the body, the blood has thinned and the fluid coming through the vein tube is mostly embalming fluid.
  • the abdominal cavity is treated by the use of a hollow tube called a trocar that is used to aspirate gases and liquid contents under suction.
  • a preservative chemical - generally a more concentrated solution of the embalming fluid - is introduced via the trocar needle .
  • the body is covered with a sheet awaiting dressing and placement in the casket .
  • Cosmetics may be applied later to improve the natural colour of the body, although this will be less important if the embalming fluid includes a colorant . Much of the natural colour is created by ⁇ blood in facial capillaries - this is no longer present after embalming. In the case of women, cosmetics used in life may also be used to recreate the "look" the person had during life. The hair is combed or set .
  • Embalming fluids in accordance with this invention will be administered in accordance with the professional judgment of the embalmer .
  • Formaldehyde acts as a chemical fixing agent, reacting with the soluble albumins (proteins) in the cells of the body and converting them to albuminoids which are gels.
  • the chemical agent perfuses into the tissues and exerts its disinfecting and preservative functions.
  • Formaldehyde is obtained commercially as an aqueous solution (formalin), which is usually a ca. 28% solution, and this is diluted down by the funeral director or embalmer to ca. 1-3% concentration. Typically, and depending on body size, more particularly vascular capacity, 2-10 litres of diluted solution are used per embalming.
  • Formaldehyde-based embalming fluids may or may not contain other chemicals such as colorants, humectants, disinfectants, sequestrants, pH stabilisers, etc.
  • Formaldehyde has long been used in the embalming profession as it confers excellent preservative properties on the body and is an effective disinfectant and anti-microbial agent.
  • formaldehyde can create problems as it should not enter sewerage systems or water courses. Its effect on soil and soil organisms is not certain, but formaldehyde has been shown to be toxic to fish and related species when introduced into water systems . Recommended disposal is via incineration.
  • Aldehydes other than formaldehyde, especially glutaraldehyde have also found use in embalming. However, at least some of the above problems have also occurred here.
  • an embalming fluid essentially free of aldehyde which fluid comprises:
  • additives selected from perfumes, colorants, sequestrants and anti-coagulants.
  • the present invention provides a method of manufacture which comprises the use of a vegetable-based, water-soluble polymer and a non-toxic, iodine-based disinfectant in the formulation of an embalming fluid which is essentially free from aldehyde.
  • a method of embalming which comprises injecting to the body which is to be embalmed a fluid in accordance with the invention.
  • the vegetable-based polymer advantageously produces a pseudoplastic solution when dissolved in water.
  • the polymer is a sodium alginate.
  • hydrophilic polysaccharides consisting of blocks of D-mannuronic acid linked in the ⁇ configuration through the 1- and 4- positions and L- guluronic acid units linked in the configuration through the 1- and 4- positions.
  • the currently preferred polymer can be "Algin I-S' manufactured and distributed by Kimitsu Chemical Industries Co., Ltd., or Protanol GP 9356 manufactured and distributed *by FMC Biopolymer, and is a white free- flowing powder which is odourless and tasteless.
  • An aqueous solution containing 1% by weight of this product has a viscosity of ca. 700-1200 mPa.s at 20°C.
  • the preferred product is readily available, is derived from a renewable natural resource and is fully and readily biodegradable.
  • the vegetable-based polymer has pseudoplastic properties which make for ease of preparation and injection but give some thickening when the force is removed. It also contributes some antiseptic benefits.
  • the disinfectant is preferably iodine-based, and polyvinylpyrrolidone-iodine is especially preferred.
  • This material has a broad antimicrobial spectrum and is readily available; it is sometimes known as "PVP iodine”. Bacteria, viruses, bacterial endospores and fungi are destroyed through oxidative interaction and direct iodination of biological macromolecules .
  • Polyvinylpyrrolidone-iodine is available from varous commercial sources including Graymor Chemical Co. of Elizabeth, New Jersey and Graymor Chemical Hamburg GmbH, Hamburg, Germany.
  • the perfume should be a naturally based material, preferably a fragrant oil, e.g. rose oil (Rosa centi folium) , sandalwood oil ⁇ Santalum album) or geranium oil (Pelargonium graveolens) , which may be incorporated in dilute form.
  • a fragrant oil e.g. rose oil (Rosa centi folium) , sandalwood oil ⁇ Santalum album) or geranium oil (Pelargonium graveolens)
  • suitable fragrances include chrysanthemum oil and freesia oil .
  • Such materials are readily available; a suitable source for rose oil and sandalwood oil is, for example, Elixarome Ltd of Tonbridge, Kent (England) .
  • a colorant is preferably added to give a more realistic skin colour to the cadaver; the colorant used will vary depending on the ethnic origin of the cadaver.
  • the colorant should be a natural vegetable dye, preferably cochineal. Suitable colorants are readily available commercially, e.g. from Cybercolors Ltd. of Monkstown, Co. Cork, Ireland or Warner Jenkinson of St. Louis, Missouri, USA.
  • An anti-coagulant is preferably added to aid penetration of the embalming fluid and to break down thickened blood areas.
  • the anti-coagulant is preferably sodium citrate, readily available commercially, e.g. from ADM Ingredients Ltd. of Erith, Kent (England) .
  • a sequestrant is preferably incorporated to prevent interaction by any high levels of divalent salts in the water used.
  • a preferred sequestrant is sodium hexametaphosphate, which may be readily obtained commercially, for example from Rhodia Consumer Specialties, Warley, West Midlands (UK) .
  • Potable water including de-ionised water or demineralised water, is to be used for formulating an embalming fluid in accordance with this invention.
  • the components of the embalming fluid of this invention will be combined in appropriate proportions; in particular, the quantities of the polymer component and the disinfecting component will be selected according to the site into which the embalming fluid is to be injected. Conventionally, more concentrated solutions are injected into the major organs of the body, while more dilute solutions are injected into the vascular system.
  • the ratio (by weight) of polymer to disinfectant is in the range from 10:1 to 0.5:1 when the polymer is a sodium alginate and the disinfectant is PVP-iodine with a ' weight ratio of about 1.8:1 being most preferred.
  • the invention provides an embalming fluid essentially free of aldehyde, which fluid comprises :
  • additives e.g. one or more perfumes, sequestrants and colorants, and the ratio (by weight) of polymer to disinfectant being in the range from 10:1 to 0.5:1.
  • the embalming fluid may comprise 0.05-3% by weight of the vegetable-based polymer, about 0.05-2% by weight of the disinfectant, about 0.001 to 1% by weight of perfume, about 0.01 to 0. ' 1 by weight of colorant, 0.1 - 1.0% of sequestrant and 0.01 - 0.07% of anticoagulent , the balance being potable water.
  • the embalming fluid comprises 0.1-2% by weight of the vegetable-based polymer, 0.05-1.5% by weight of the disinfectant, 0.001-0.05% of perfume, 0.01-0.1% by weight of colorant, 0.1 - 0.5% by weight of sequestrant, 0.01-0.03% by weight of anti -coagulant and potable water in an amount such as to constitute from 96.3 to 99.7% by weight of the embalming fluid.
  • a preferred formulation is 0.35% by weight of the vegetable based polymer "Protanal GP 9356" from FMC Biopolymer; 0.2% by weight of the disinfectant polyvinylpyrrolidone-iodine from Graymor Chemical Hamburg GmbH; 0.008% by weight of perfume; 0.02% by weight of colorant; 0.14% by weight of sequestrant;
  • kits for use in formulating a formaldehyde-free embalming fluid comprising, in packaged form, an alginate polymer; an iodine-based disinfectant; a perfume; a colorant; a sequestrant and an anti-coagulant .
  • the major organs of the body will usually be injected with a more concentrated solution, typically 2-4 times the concentration of that used for the vascular system; the limiting concentration of solution is determined by the viscosity of the embalming fluid.
  • a concentrated solution to be diluted before use as an embalming solution comprising
  • 0.1-3% by weight of a vegetable-based polymer 0.1-3% by weight of a preferably iodine-based disinfectant; 0.01-0.2% by weight of a perfume; 0.01-0.5% by weight of a colorant; 0.1-2% of sequestrant and 0.01-0.5% by weight of anti-coagulant; the balance being potable water.
  • the concentrated solution is poured into 7-10 litres of potable water in a suitable container and the whole is stirred with the minimum of stirring until a homogenous embalming fluid is obtained.
  • the embalming fluid of this invention is a generally natural products-based composition; it is odourless and non- toxic. It can be used without risk of irritation to skin, mouth and nasal passages. It obviates the need for excessive air changes in the embalming room.
  • the embalming fluid has proved successful in the treatment and preparation of cadavers prior to a funeral . Natural skin colours can be maintained and there were no unpleasant Odours presen .
  • Cadavers have been held for up to 7 days under refrigeration conditions without deterioration. It is estimated that under refrigeration, very extended periods would prove to present few problems. Tests were also carried out with no refrigeration for a period of 21 days after treatment. After 18 days some leakage was noted from the rectum but no packing had been used under the test conditions . The body began to deteriorate after this time period but not too seriously. Barometric pressure at this period was unusually low, with thunder, the ambient temperature being 12-14°C.
  • the body of a 53 -year old Caucasian female weighing 140lbs (64kg) was embalmed using an embalming fluid in accordance with this invention.
  • the embalming process took place five days after the woman had died from carcinomatosis, the cadaver having been refrigerated at +2°C during this time. Rigor mortis had abated and the body was easily manouvrable when the embalming took place .
  • the embalming- fluid consisted of a solution in water of the following ingredients :
  • the major proportion of the fluid used was made up with water to give a solution having 1 part by weight of the above ingredients and 99 parts by weight water.
  • a smaller amount of solution at twice this concentration (2 parts by weight of the above ingredients and 98 parts by weight water) can also be used for the major organs .
  • the body was ' washed prior to the embalming process and lower orifice plugging took place using an absorbent pad which had been immersed in the embalming fluid.
  • the- embalmer was wearing surgical (latex) gloves instead of the heavy, protective type needed when an embalming fluid based on formaldehyde is used. This permits greater dexterity and hence allows the embalming to proceed more readily.
  • the cadaver Immediately after the embalming process had been completed, the cadaver had a natural skin tone and showed no signs of discoloration. There was no unpleasant odour.
  • the cadaver was kept at a temperature of 7°C for a period of- seven days after which the skin tone was still natural in appearance, and the skin retained its suppleness . There was no evidence of discoloration or of deterioration of the tissue. There was still no unpleasant odour (a mild floral fragrance was evident) , and no evidence of seepage of fluids from the body.
  • the embalming took place four days after death, by which time rigor mortis had abated and hypostasis was evident in the left side of the face, the left arm and hand. Both legs were slightly oedematous and the eyes were very sunken.
  • the site chosen for injection of the embalming fluid was the right common carotid artery.
  • the cadaver presented a relatively natural appearance, with arms, trunk and legs assuming a relatively natural colour. There was no oedema in the legs . The hands were soft and pliable. The face still had some mottled marks, but these were clearing, and the eyes and mouth had a full, natural appearance.
  • the cadaver was stored for five days prior to burial. After this period, there was no evidence of deterioration, either in terms of appearance or of odour. There was no bruising or discoloration of the tissues.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dentistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)

Abstract

An embalming fluid is provided which comprises a vegetable based, water-soluble polymer and a non-toxic disinfectant and which is essentially free from aldehyde. The preferred disinfectant is an iodine-based disinfectant, polyvinylpyrrolidone-iodine being particularly preferred. Embalming methods are also disclosed, together with kits for use in preparing an embalming fluid in accordance with the invention.

Description

EMBALMING FLUID
This invention relates to an embalming fluid for use in an embalming process.
Embalming was developed and widely practised in ancient Egypt where, from around 6000 BC to 600 AD, 400 million bodies were mummified. The processes involved in traditional Egyptian embalming have led to the remarkable preservation of many bodies.
The embalming process nowadays differs markedly from the religious practices of ancient Egypt; the purpose is partly cosmetic (to improve the appearance of the body, and thereby reduce the distress caused to relatives of the deceased) and partly preservative, although the main aim is to ensure that the body remains in a hygienic condition during the period up to burial or cremation, rather than providing long-lasting preservation of the tissues.
The modern embalming process involves flushing out the blood from the circulatory system of the body and replacing it with an embalming fluid which has a stabilising and protecting action on the body. The embalming fluid is injected into the arterial system of the cadaver and directly into some organs. Displaced body fluids are treated and disposed of via the public sewerage system or more usually by a contracted disposal firm.
The normal steps in the modern embalming process are as follows: • The body is placed in. a proper position on the embalming table with the pubic area covered with a modesty cloth.
• The body is washed and disinfected. • The face is shaved as necessary.
• The eyes are closed. This is usually accomplished with a small curved plastic disc called an "eye cap" placed under the eyelid. Perforations in the cap are sometimes present to help hold the eye lid in place.
• The mouth is closed. This is usually accomplished by the placing of a specially designed "tack" in the upper and lower jaw. Each tack has a fine wire attached. By twisting the two wires together, the jaw is thus closed and the lips are set to the natural lip line using a cream to retain the proper position and to prevent dehydration.
• The lower body orifice (s) may be plugged to prevent leakage . • The embalming solution is prepared. The modern embalming machine consists of a 2-3 gallon reservoir and an electric pump.
• An incision is made over the carotid artery (where the neck meets the shoulder) or over the femoral artery (in the leg at the groin) . The artery and a nearby vein are located and isolated.
• A tube which is attached to the machine is inserted into the artery. A slightly larger tube is placed into the accompanying vein. This tube is attached via a hose to a collecting tank.
• The fluid is injected into the artery under pressure by the embalming machine. As the blood is displaced by the fluid going in, it is forced out of the body from the vein and is disposed of. The pressure forces the embalming fluid into the capillaries and eventually to the cells of the body. After sufficient solution (typically approximately 2-10 litres depending on body size, more particularly vascular capacity) of solution are injected into the body, the blood has thinned and the fluid coming through the vein tube is mostly embalming fluid.
• The tubes are removed and the incision sutured.
• The abdominal cavity is treated by the use of a hollow tube called a trocar that is used to aspirate gases and liquid contents under suction.
A preservative chemical - generally a more concentrated solution of the embalming fluid - is introduced via the trocar needle .
• The body is again washed and cream is placed on the hands and face to prevent dehydration.
• The hair is shampooed and the finger nails cleaned.
• The body is covered with a sheet awaiting dressing and placement in the casket . • Cosmetics may be applied later to improve the natural colour of the body, although this will be less important if the embalming fluid includes a colorant . Much of the natural colour is created by blood in facial capillaries - this is no longer present after embalming. In the case of women, cosmetics used in life may also be used to recreate the "look" the person had during life. The hair is combed or set .
The foregoing sequence of steps is given for the purpose of illustration only and is not intended to be limiting on the invention. Embalming fluids in accordance with this invention will be administered in accordance with the professional judgment of the embalmer . The earliest modern embalming fluids contained arsenic, but these solutions were soon replaced by formaldehyde-based embalming fluids. Despite its unpleasant and dangerous properties, the use of formaldehyde in embalming has become almost universal .
Formaldehyde acts as a chemical fixing agent, reacting with the soluble albumins (proteins) in the cells of the body and converting them to albuminoids which are gels. By pumping a formaldehyde solution through the vascular system of a body, the chemical agent perfuses into the tissues and exerts its disinfecting and preservative functions.
Formaldehyde is obtained commercially as an aqueous solution (formalin), which is usually a ca. 28% solution, and this is diluted down by the funeral director or embalmer to ca. 1-3% concentration. Typically, and depending on body size, more particularly vascular capacity, 2-10 litres of diluted solution are used per embalming.
Formaldehyde-based embalming fluids may or may not contain other chemicals such as colorants, humectants, disinfectants, sequestrants, pH stabilisers, etc.
Formaldehyde has long been used in the embalming profession as it confers excellent preservative properties on the body and is an effective disinfectant and anti-microbial agent.
Although formaldehyde is very effective in preserving tissues for the timescale required, it is nevertheless a very hazardous material; it is highly toxic when inhaled and possesses irritant properties when in contact with the skin or eyes . It also has carcinogenic activity and has been linked to many different forms of cancer - nasal, lung, testicular and brain cancer as well as leukaemia. Studies conducted by the National Cancer Institute in the USA have shown that embalmers were at greater risk for leukaemia, testicular and brain cancer than the general population.
The permitted limit of exposure to formaldehyde has been gradually reduced and funeral directors and embalmers have to work in an environment where rapid changes of air are possible.
In addition, the disposal of formaldehyde can create problems as it should not enter sewerage systems or water courses. Its effect on soil and soil organisms is not certain, but formaldehyde has been shown to be toxic to fish and related species when introduced into water systems . Recommended disposal is via incineration.
Aldehydes other than formaldehyde, especially glutaraldehyde have also found use in embalming. However, at least some of the above problems have also occurred here.
There is therefore a long term problem both for the environment and for the embalmer himself in using aldehyde in embalming fluids. Consequently there is a need for an embalming fluid which is essentially free from aldehyde .
Accordingly, this invention aims to provide an essentially aldehyde-free embalming fluid that is non- toxic, easy to make up and use, effective, and which is also environmentally acceptable and biodegradable. According to one aspect of the present invention, there is provided an embalming fluid essentially free of aldehyde, which fluid comprises:
(a) a vegetable-based, water-soluble polymer;
(b) a non-toxic disinfectant which is free from forma1dehyde ; and
(c) potable water,
optionally with one or more additives selected from perfumes, colorants, sequestrants and anti-coagulants.
According to a second aspect, the present invention provides a method of manufacture which comprises the use of a vegetable-based, water-soluble polymer and a non-toxic, iodine-based disinfectant in the formulation of an embalming fluid which is essentially free from aldehyde.
According to a third aspect of this invention, there is provided a method of embalming, which comprises injecting to the body which is to be embalmed a fluid in accordance with the invention.
The vegetable-based polymer advantageously produces a pseudoplastic solution when dissolved in water. Preferably the polymer is a sodium alginate. These are hydrophilic polysaccharides consisting of blocks of D-mannuronic acid linked in the β configuration through the 1- and 4- positions and L- guluronic acid units linked in the configuration through the 1- and 4- positions.
The currently preferred polymer can be "Algin I-S' manufactured and distributed by Kimitsu Chemical Industries Co., Ltd., or Protanol GP 9356 manufactured and distributed *by FMC Biopolymer, and is a white free- flowing powder which is odourless and tasteless. An aqueous solution containing 1% by weight of this product has a viscosity of ca. 700-1200 mPa.s at 20°C.
The preferred product is readily available, is derived from a renewable natural resource and is fully and readily biodegradable.
The vegetable-based polymer has pseudoplastic properties which make for ease of preparation and injection but give some thickening when the force is removed. It also contributes some antiseptic benefits.
The disinfectant is preferably iodine-based, and polyvinylpyrrolidone-iodine is especially preferred. This material has a broad antimicrobial spectrum and is readily available; it is sometimes known as "PVP iodine". Bacteria, viruses, bacterial endospores and fungi are destroyed through oxidative interaction and direct iodination of biological macromolecules . Polyvinylpyrrolidone-iodine is available from varous commercial sources including Graymor Chemical Co. of Elizabeth, New Jersey and Graymor Chemical Hamburg GmbH, Hamburg, Germany.
The perfume should be a naturally based material, preferably a fragrant oil, e.g. rose oil (Rosa centi folium) , sandalwood oil { Santalum album) or geranium oil (Pelargonium graveolens) , which may be incorporated in dilute form. Other suitable fragrances include chrysanthemum oil and freesia oil . Such materials are readily available; a suitable source for rose oil and sandalwood oil is, for example, Elixarome Ltd of Tonbridge, Kent (England) . A colorant is preferably added to give a more realistic skin colour to the cadaver; the colorant used will vary depending on the ethnic origin of the cadaver. The colorant should be a natural vegetable dye, preferably cochineal. Suitable colorants are readily available commercially, e.g. from Cybercolors Ltd. of Monkstown, Co. Cork, Ireland or Warner Jenkinson of St. Louis, Missouri, USA.
An anti-coagulant is preferably added to aid penetration of the embalming fluid and to break down thickened blood areas. The anti-coagulant is preferably sodium citrate, readily available commercially, e.g. from ADM Ingredients Ltd. of Erith, Kent (England) .
A sequestrant is preferably incorporated to prevent interaction by any high levels of divalent salts in the water used. A preferred sequestrant is sodium hexametaphosphate, which may be readily obtained commercially, for example from Rhodia Consumer Specialties, Warley, West Midlands (UK) .
Potable water, including de-ionised water or demineralised water, is to be used for formulating an embalming fluid in accordance with this invention.
The components of the embalming fluid of this invention will be combined in appropriate proportions; in particular, the quantities of the polymer component and the disinfecting component will be selected according to the site into which the embalming fluid is to be injected. Conventionally, more concentrated solutions are injected into the major organs of the body, while more dilute solutions are injected into the vascular system.
Preferably, the ratio (by weight) of polymer to disinfectant is in the range from 10:1 to 0.5:1 when the polymer is a sodium alginate and the disinfectant is PVP-iodine with a' weight ratio of about 1.8:1 being most preferred.
In one embodiment, the invention provides an embalming fluid essentially free of aldehyde, which fluid comprises :
(a) a sodium alginate polymer;
(b) polyvinylpyrrolidone-iodine; and (c) potable water,
optionally with conventional additives, e.g. one or more perfumes, sequestrants and colorants, and the ratio (by weight) of polymer to disinfectant being in the range from 10:1 to 0.5:1.
The embalming fluid may comprise 0.05-3% by weight of the vegetable-based polymer, about 0.05-2% by weight of the disinfectant, about 0.001 to 1% by weight of perfume, about 0.01 to 0.'1 by weight of colorant, 0.1 - 1.0% of sequestrant and 0.01 - 0.07% of anticoagulent , the balance being potable water.
Preferably, the embalming fluid comprises 0.1-2% by weight of the vegetable-based polymer, 0.05-1.5% by weight of the disinfectant, 0.001-0.05% of perfume, 0.01-0.1% by weight of colorant, 0.1 - 0.5% by weight of sequestrant, 0.01-0.03% by weight of anti -coagulant and potable water in an amount such as to constitute from 96.3 to 99.7% by weight of the embalming fluid. A preferred formulation is 0.35% by weight of the vegetable based polymer "Protanal GP 9356" from FMC Biopolymer; 0.2% by weight of the disinfectant polyvinylpyrrolidone-iodine from Graymor Chemical Hamburg GmbH; 0.008% by weight of perfume; 0.02% by weight of colorant; 0.14% by weight of sequestrant;
0.013% of anti-coagulant and 99.4% by weight of potable water.
According to a fourth aspect of the present invention, there is provided a kit for use in formulating a formaldehyde-free embalming fluid, the kit comprising, in packaged form, an alginate polymer; an iodine-based disinfectant; a perfume; a colorant; a sequestrant and an anti-coagulant .
The major organs of the body will usually be injected with a more concentrated solution, typically 2-4 times the concentration of that used for the vascular system; the limiting concentration of solution is determined by the viscosity of the embalming fluid.
According to a fifth aspect of the present invention, there is provided a concentrated solution to be diluted before use as an embalming solution. The solution, essentially free from aldehyde, comprises
0.1-3% by weight of a vegetable-based polymer; 0.1-3% by weight of a preferably iodine-based disinfectant; 0.01-0.2% by weight of a perfume; 0.01-0.5% by weight of a colorant; 0.1-2% of sequestrant and 0.01-0.5% by weight of anti-coagulant; the balance being potable water.
A preferred method of making up an embalming fluid using the concentrated solution in accordance with this invention will now be described. The concentrated solution is poured into 7-10 litres of potable water in a suitable container and the whole is stirred with the minimum of stirring until a homogenous embalming fluid is obtained.
If using a powder mix, then a small portion, say
10%, of the potable water to be used is taken and a powder mix of the other components of the embalming fluid is sprinkled slowly into it. The mixture is stirred vigorously until the powder is well dispersed. The mixture is allowed to stand until all the powder has been taken up by the water and the resulting product is then added to the final quantity of the water and the whole mixture stirred until a homogenous solution is obtained. Stirring is discontinued and the solution is left to stand to equilibrate to ambient conditions .
The embalming fluid of this invention is a generally natural products-based composition; it is odourless and non- toxic. It can be used without risk of irritation to skin, mouth and nasal passages. It obviates the need for excessive air changes in the embalming room.
The embalming fluid has proved successful in the treatment and preparation of cadavers prior to a funeral . Natural skin colours can be maintained and there were no unpleasant Odours presen .
No deterioration of the cadaver was recorded over a 7 day period (average) .
Cadavers have been held for up to 7 days under refrigeration conditions without deterioration. It is estimated that under refrigeration, very extended periods would prove to present few problems. Tests were also carried out with no refrigeration for a period of 21 days after treatment. After 18 days some leakage was noted from the rectum but no packing had been used under the test conditions . The body began to deteriorate after this time period but not too seriously. Barometric pressure at this period was unusually low, with thunder, the ambient temperature being 12-14°C.
The invention will be illustrated in a non- limiting manner by the following Example.
Example 1
The body of a 53 -year old Caucasian female weighing 140lbs (64kg) was embalmed using an embalming fluid in accordance with this invention. The embalming process took place five days after the woman had died from carcinomatosis, the cadaver having been refrigerated at +2°C during this time. Rigor mortis had abated and the body was easily manouvrable when the embalming took place .
The embalming- fluid consisted of a solution in water of the following ingredients :
1: Protanol GP 9356 - (FMC Biopolymer) ;
2: PVP-iodine - (Graymor Chemical Hamburg GmbH);
3 : Rose oil - (Elixarome Limited; and 4: Carmine - (Cybercolors Ltd.) .
5 : Sodium hexametaphosphate - (Rhodia Consumer
Specialities)
6: Sodium citrate - (ADM Ingredients Ltd.)
The relative proportions of these ingredients, by weight, was 1:2:3:4:5:6 = 0.35:0.2:0.008:0.02:0.14: 0.013. These proportions may otherwise be expressed as 1:2:3:4:5:6 = 1:0.57:0.023:0.057:0.4:0.037.
The major proportion of the fluid used was made up with water to give a solution having 1 part by weight of the above ingredients and 99 parts by weight water. A smaller amount of solution at twice this concentration (2 parts by weight of the above ingredients and 98 parts by weight water) can also be used for the major organs .
The body was' washed prior to the embalming process and lower orifice plugging took place using an absorbent pad which had been immersed in the embalming fluid.
2 litres of the normal concentration embalming fluid were pumped into the vascular system of the cadaver, after which time the venous effusion was composed of embalming fluid rather than blood. 0.3 litres of the more concentrated fluid was then injected by means of a trocar into the abdominal cavity. The total quantity of fluid injected was thus 2.3 litres.
During the embalming process, the- embalmer was wearing surgical (latex) gloves instead of the heavy, protective type needed when an embalming fluid based on formaldehyde is used. This permits greater dexterity and hence allows the embalming to proceed more readily.
Immediately after the embalming process had been completed, the cadaver had a natural skin tone and showed no signs of discoloration. There was no unpleasant odour.
The cadaver was kept at a temperature of 7°C for a period of- seven days after which the skin tone was still natural in appearance, and the skin retained its suppleness . There was no evidence of discoloration or of deterioration of the tissue. There was still no unpleasant odour (a mild floral fragrance was evident) , and no evidence of seepage of fluids from the body.
Example 2
The body of an elderly male, approximately 80 years old, of average build and 6 ft. tall, was embalmed using an embalming fluid as described in Example 1 above. The embalming took place four days after death, by which time rigor mortis had abated and hypostasis was evident in the left side of the face, the left arm and hand. Both legs were slightly oedematous and the eyes were very sunken. The site chosen for injection of the embalming fluid was the right common carotid artery.
After one litre of fluid had been injected, it was apparent that the fluid was distributing around the body. Hypostasis was starting to clear and the face - in particular the lips and eyeballs - was filling out to a natural condition.
After 4 litres had been injected, drainage by the "heart tap" method was commenced, the trocar needle entering the right atrium. Abdominal drainage was also carried out, after which 1 litre of the more concentrated embalming solution was injected into the abdominal cavity.
At the end of the embalming process, the cadaver presented a relatively natural appearance, with arms, trunk and legs assuming a relatively natural colour. There was no oedema in the legs . The hands were soft and pliable. The face still had some mottled marks, but these were clearing, and the eyes and mouth had a full, natural appearance.
The cadaver was stored for five days prior to burial. After this period, there was no evidence of deterioration, either in terms of appearance or of odour. There was no bruising or discoloration of the tissues. The face, including the eyes, ears and lips, had a natural pink colour which was not evident prior to embalming.

Claims

CLAIMS :
1. An embalming fluid essentially free of aldehyde, which fluid comprises:
(a) a vegetable-based, water-soluble polymer;
(b) a non-toxic disinfectant which is free from formaldehyde; and
(c) potable water,
optionally with one or more additives selected from perfumes, colorants, sequestrants and anti-coagulants .
2. An embalming fluid as claimed in claim 1, wherein said disinfectant is an iodine-based disinfectant .
3. An embalming fluid as claimed in claim 2 , wherein said disinfectant is polyvinylpyrrolidone- iodine.
4. An embalming fluid as claimed in any preceding claim, where said polymer is a sodium alginate.
5. An embalming fluid as claimed in claim 1, wherein the fluid comprises 0.05-3% by weight of the vegetable-based polymer, 0.05-2% by weight of disinfectant, 0.001-1% by weight of perfume, 0.01-0.08% by weight of colorant, 0.1-0.8% by weight of sequestrant, 0.01-0.05% by weight of anti-coagulant, the balance being potable water.
6. An embalming fluid as claimed in any preceding claim, wherein the ratio (by weight) of polymer to disinfectant is in the range from 10:1 to 0.5:1.
7. An embalming fluid essentially free of aldehyde, which fluid comprises:
(a) a sodium alginate polymer; (b) polyvinylpyrrolidone-iodine; and
(c) potable water,
optionally with one or more additives selected from perfumes, colorants, sequestrants and anti-coagulants, and the ratio (by weight) of polymer to disinfectant being in the range from 10:1 to 0.5:1.
8. A concentrated solution to be diluted before use as an embalming solution, which solution is essentially free from aldehyde and comprises 0.1-3% by weight of a vegetable-based polymer; 0.1-3% by weight of a disinfectant, an iodine-based disinfectant; 0.01- 0.2% by weight of a perfume; and 0.01-0.5% by weight of a colorant 0.1-2% by weight of a sequestrant; and 0.01- 0.5% by weight of an anti-coagulant, the balance being potable water.
9. An embalming fluid which is essentially free of aldehyde and comprises:
(a) 0.1-2% by weight of a sodium alginate polymer;
(b) 0.05-1% by weight of polyvinylpyrrolidone- iodine ; (c) 0.001-0.05% by weight of a perfume;
(d) 0.01-0.1% by weight of a colorant,
(e) 0.1-0.5% by weight of a sequestrant and
(f) 0.01-0.03% by weight of an anti-coagulant, the balance being potable water.
10. An embalming fluid as claimed in any preceding claim, wherein the potable water is demineralised water or de-ionised water.
11. A method of manufacture which comprises the use of a vegetable-based, water-soluble polymer and a non-toxic, iodine-based disinfectant in the formulation of an embalming fluid which is essentially free from formaldehyde .
12. A method of embalming, which comprises injecting to the body which is to be embalmed a fluid essentially free of aldehyde, and which comprises:
(a) a vegetable-based, water-soluble polymer;
(b) a non-toxic disinfectant which is free from formaldehyde; and
(c) potable water,
optionally with one or more additives selected from perfumes, colorants, sequestrants and anti-coagulants.
13. A method as claimed in claim 12, wherein the fluid comprises:
(a) a sodium alginate polymer;
(b) polyvinylpyrrolidone-iodine; and
(c) potable water,
optionally with one or more additives selected from perfumes, colorants, sequestrants and anti-coagulants, with the ratio (by weight) of polymer to polyvinylpyrrolidone-iodine being in the range from 10:1 to 0.5:1.
14. A method according to claim 12 or 13 wherein the potable water is demineralised water or de-ionised water.
15. A kit for use in formulating an essentially aldehyde-free embalming fluid, the kit comprising, in packaged form, an alginate polymer; an iodine-based disinfectant; a perfume; a colorant, a sequestrant and an anti-coagulant.
16. A kit as claimed in claim 15, wherein said polymer is a sodium alginate and said disinfectant is polyvinylpyrrolidone-iodine .
PCT/GB2001/005337 2000-12-01 2001-12-03 Embalming fluid WO2002043484A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU5276802A AU5276802A (en) 2000-12-01 2001-12-03 Embalming fluid
AU2002252768A AU2002252768B2 (en) 2000-12-01 2001-12-03 Embalming fluid
EP01998221A EP1365646B1 (en) 2000-12-01 2001-12-03 Embalming fluid
CA2430502A CA2430502C (en) 2000-12-01 2001-12-03 Embalming fluid
DE60129851T DE60129851T2 (en) 2000-12-01 2001-12-03 embalming fluid
US10/449,502 US8015677B2 (en) 2000-12-01 2003-06-02 Embalming fluid

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0029410.8A GB0029410D0 (en) 2000-12-01 2000-12-01 Embalming fluid
GB0029410.8 2000-12-01

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/809,433 Continuation-In-Part US20020066168A1 (en) 2000-12-01 2001-03-16 Embalming fluid

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/449,502 Continuation-In-Part US8015677B2 (en) 2000-12-01 2003-06-02 Embalming fluid

Publications (2)

Publication Number Publication Date
WO2002043484A2 true WO2002043484A2 (en) 2002-06-06
WO2002043484A3 WO2002043484A3 (en) 2002-08-15

Family

ID=9904313

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/005337 WO2002043484A2 (en) 2000-12-01 2001-12-03 Embalming fluid

Country Status (9)

Country Link
US (1) US20020066168A1 (en)
EP (1) EP1365646B1 (en)
AT (1) ATE369036T1 (en)
AU (2) AU5276802A (en)
CA (1) CA2430502C (en)
DE (1) DE60129851T2 (en)
ES (1) ES2291380T3 (en)
GB (1) GB0029410D0 (en)
WO (1) WO2002043484A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008125884A2 (en) * 2007-04-16 2008-10-23 Safemed Limited Preservation composition
WO2009122056A1 (en) * 2008-03-13 2009-10-08 Ogf Composition for tissue preservation
WO2011033221A3 (en) * 2009-09-17 2011-05-12 Ogf Composition for the external treatment of cadavers
ITRM20110570A1 (en) * 2011-10-28 2012-01-27 Laura Bui FIXATIVE SOLUTION FOR TANATOPRASSI

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110167601A1 (en) * 2008-10-22 2011-07-14 Innovative Supply, Inc. Restoration/embalming kit
WO2011126801A2 (en) * 2010-03-28 2011-10-13 Christian Connally A device and method for preventing leakage of fluids from a body during an embalming procedure

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4755378A (en) * 1985-08-17 1988-07-05 Euroceltique, S.A. Iodophor-containing suppository
US5679333A (en) * 1996-10-25 1997-10-21 Dunphy; Brian William Formaldehyde-free tissue preservative compositions
WO2000018237A1 (en) * 1998-09-30 2000-04-06 West Agro, Inc. Stable glycerin iodine concentrate compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4755378A (en) * 1985-08-17 1988-07-05 Euroceltique, S.A. Iodophor-containing suppository
US5679333A (en) * 1996-10-25 1997-10-21 Dunphy; Brian William Formaldehyde-free tissue preservative compositions
WO2000018237A1 (en) * 1998-09-30 2000-04-06 West Agro, Inc. Stable glycerin iodine concentrate compositions

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008125884A2 (en) * 2007-04-16 2008-10-23 Safemed Limited Preservation composition
WO2008125884A3 (en) * 2007-04-16 2009-09-03 Safemed Limited Preservation composition
WO2009122056A1 (en) * 2008-03-13 2009-10-08 Ogf Composition for tissue preservation
WO2011033221A3 (en) * 2009-09-17 2011-05-12 Ogf Composition for the external treatment of cadavers
ITRM20110570A1 (en) * 2011-10-28 2012-01-27 Laura Bui FIXATIVE SOLUTION FOR TANATOPRASSI

Also Published As

Publication number Publication date
DE60129851T2 (en) 2008-05-08
CA2430502C (en) 2012-07-31
ES2291380T3 (en) 2008-03-01
EP1365646B1 (en) 2007-08-08
AU2002252768B2 (en) 2007-01-25
WO2002043484A3 (en) 2002-08-15
EP1365646A2 (en) 2003-12-03
US20020066168A1 (en) 2002-06-06
CA2430502A1 (en) 2002-06-06
ATE369036T1 (en) 2007-08-15
DE60129851D1 (en) 2007-09-20
GB0029410D0 (en) 2001-01-17
AU5276802A (en) 2002-06-11

Similar Documents

Publication Publication Date Title
JP2768558B2 (en) Preservatives for dissection and biology, improved cadaver preservative compositions and preservative treatment methods
US8015677B2 (en) Embalming fluid
Ajileye et al. Human Embalming Techniques: A Review.
EP1365646B1 (en) Embalming fluid
US20150013125A1 (en) Composition and method for tissue preservation and embalming
AU2002252768A1 (en) Embalming fluid
WO2008125884A2 (en) Preservation composition
US5607668A (en) Embalming composition and method
CN107637588A (en) A kind of restorative procedure of corrupt remains
US20240032529A1 (en) Compositions and Methods for Preservation and Fixation
KR100775557B1 (en) Essential oil combination to be used for washing a corpse
JP3405733B2 (en) Compositions containing dialkyl peroxide (C ▲ 1〜 to C ▲ 66) ketones for preserving organic tissue and use of the compositions in preservation and anatomical preparation of organic tissues of animals or humans
EP3542627B1 (en) Composition for preservation of corpses, method of obtaining said composition and its use
KR100305470B1 (en) Use of Dialkyl (C1-C6) -Keron Peroxide Compositions for Preservation of Organic Tissues, and Compositions in Preservation and Preparation for Dissection of Animal or Human Organic Tissues
US6387360B1 (en) Anti-jaundice composition for corpses and method
JP2011051963A (en) Method for producing anti-oxidative deodorant and cosmetic agent for dead body preservation, and anti-oxidative deodorant and cosmetic agent for dead body produced by the same method
Hambly Dr. Hambly's Historical Guide To Embalming Cookbook
RU2540498C1 (en) Solution for embalming of dead bodies used by transplant surgeons to train organ harvesting for transplantation
JPS6344505A (en) Germicidal mildewproofing agent
Wilcox Embalming
FR2805437A1 (en) COMPOSITION AND FLUID FOR STORING HUMAN OR ANIMAL BODIES CONTAINING THIS COMPOSITION
Hoggarth et al. A pathologist’s guide to embalming
FR3073125A1 (en) COMPOSITION FOR THE PRESERVATION OF FABRICS
MXPA96005298A (en) Compositions containing dialquil peroxide (c1-c6) -cetone for the conservation of organic tissues, and application of such compositions in the conservation and anatomical preparation of organic tissues of animal or human origin
Clarke Practical Embalming: A Recitation of Actual Experiences of the Author and Hundreds of the Most Expert Embalmers of the World

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2430502

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10449502

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001998221

Country of ref document: EP

Ref document number: 2002252768

Country of ref document: AU

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001998221

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP

WWG Wipo information: grant in national office

Ref document number: 2001998221

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)